CELEX: 62018TA0321
Language: en
Date: 2019-03-06 00:00:00
Title: Case T-321/18: Judgment of the General Court of 6 March 2019 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT) (EU trade mark — Opposition proceedings — Application for EU word mark NOCUVANT — Earlier word marks NOCUTIL — Proof of genuine use — Article 47(2) of Regulation (EU) 2017/1001 — Relative ground for refusal — Likelihood of confusion — Similarity of the signs — Article 8(1)(b) of Regulation 2017/1001)

15.4.2019   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 139/51
            
         
      Judgment of the General Court of 6 March 2019 — Serenity Pharmaceuticals v EUIPO — Gebro Holding (NOCUVANT)
      (Case T-321/18) (1)
      
      (EU trade mark - Opposition proceedings - Application for EU word mark NOCUVANT - Earlier word marks NOCUTIL - Proof of genuine use - Article 47(2) of Regulation (EU) 2017/1001 - Relative ground for refusal - Likelihood of confusion - Similarity of the signs - Article 8(1)(b) of Regulation 2017/1001)
      (2019/C 139/51)
      Language of the case: English
      
         Parties
      
      
         Applicant: Serenity Pharmaceuticals LLC (Milford, Pennsylvania, United States) (represented by: J. Day, Solicitor)
      
         Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė and H. O’Neill, acting as Agents)
      
         Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Gebro Holding GmbH (Fieberbrunn, Austria) (represented by: M. Konzett, lawyer)
      
         Re:
      
      Action brought against the decision of the Second Board of Appeal of EUIPO of 8 March 2018 (Case R 584/2017-2), relating to opposition proceedings between Gebro Holding and Allergan, Inc.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  
                     Dismisses the action;
                  
               
            
                  2.
               
               
                  
                     Orders Serenity Pharmaceuticals LLC to pay the costs.
                  
               
            
         (1)  OJ C 240, 9.7.2018.